Follicular Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 42 expanded access programs, clinical trials, and compassionate use pathways listed for Follicular Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with follicular lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 41 programs are currently active or recruiting, with the remaining 1 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, Reid Merryman, MD, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, and others.
By recruiting status
Snapshot of where every Follicular Lymphoma program currently sits in its lifecycle.
- Active / Recruiting41
- Inactive1
Top sponsors
Organisations running the most Follicular Lymphoma programs in the directory.
- M.D. Anderson Cancer Center3 records
- Masonic Cancer Center, University of Minnesota3 records
- Reid Merryman, MD3 records
- H. Lee Moffitt Cancer Center and Research Institute2 records
- Memorial Sloan Kettering Cancer Center2 records
- Merck Sharp & Dohme LLC2 records
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1 record
- BeiGene1 record
- Beth Israel Deaconess Medical Center1 record
- Brown University1 record
Follicular Lymphoma records (42)
Clinical trials and expanded access programs registered for Follicular Lymphoma. Expanded access first, then recruiting, then newest first. Open any record for eligibility, locations and sponsor contact details.
- Expanded access2023Kite, A Gilead CompanyExpanded Access Study for Patients Needing Axicabtagene Ciloleucel Treatment
- 2026Merck Sharp & Dohme LLCStudy on MK-1045 and Rituximab for Treating Follicular Lymphoma
- 2025Masonic Cancer Center, University of MinnesotaPhase 2 Study of Tafasitamab with Lenalidomide and Rituximab for Untreated Follicular and Marginal Zone Lymphoma
- 2025CelgeneStudy Comparing Golcadomide and Rituximab with Other Treatments for Relapsed or Hard-to-Treat Follicular Lymphoma
- 2025Reid Merryman, MDStudy on Epcoritamab, Zanubrutinib, and Rituximab for Treating Relapsed or Refractory Follicular Lymphoma
- 2025Gottfried von Keudell, MD PhDStudy on Odronextamab for Treating Low Tumor Volume Advanced Follicular Lymphoma
- 2025Memorial Sloan Kettering Cancer CenterStudy on Using Lower Dose Radiation Therapy for B-Cell Lymphomas
- 2024M.D. Anderson Cancer CenterPhase 2 Trial of Obinutuzumab and CC-99282 for Patients with Untreated High Tumor Burden Follicular Lymphoma
- 2024M.D. Anderson Cancer CenterPhase II Study of Axicabtagene Ciloleucel (CAR T-Cell Therapy) with Radiation for Treating Relapsed or Hard-to-Treat Follicular Lymphoma
- 2024Marcela V. Maus, M.D.,Ph.D.Study on Emapalumab to Prevent Side Effects from CAR-T Cell Therapy in Non-Hodgkin's Lymphoma Patients
- 2024Beth Israel Deaconess Medical CenterStudy on Epcoritamab for Follicular Lymphoma Patients Not Achieving Complete Response with Initial Chemoimmunotherapy
- 2024City of Hope Medical CenterStudy on Lenalidomide and Epcoritamab for Treating Untreated Follicular Lymphoma
Show all 42 Follicular Lymphoma records on this pageShow fewer
- 2024H. Lee Moffitt Cancer Center and Research InstituteStudy on Rituximab and Zanubrutinib for Patients with Slow-Growing B-cell Lymphomas
- 2023Reid Merryman, MDGlofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
- 2023Reid Merryman, MDStudy on Epcoritamab and Rituximab for First-time Treatment of Follicular Lymphoma
- 2023Vaishalee KenkreStudy on Tazemetostat with Rituximab and Bendamustine for Initial Treatment of High Tumor Burden Follicular Lymphoma
- 2023CRISPR Therapeutics AGStudy on the Safety and Effectiveness of CTX112 for Treating Difficult or Returning B-Cell Cancers
- 2023Masonic Cancer Center, University of MinnesotaStudy on Using Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for Blood Disorders
- 2023Weill Medical College of Cornell UniversityTazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
- 2022John ListerLocal Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- 2022Immunitas TherapeuticsStudy of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
- 2022Juan P. Alderuccio, MDStudy on Loncastuximab Tesirine and Rituximab for Treating Relapsed or Hard-to-Treat Follicular Lymphoma
- 2022Brown UniversityStudy on Mosunetuzumab and Lenalidomide as First Treatment for Follicular and Marginal Zone Lymphoma
- 2022Washington University School of MedicineStudy on Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
- 2022Memorial Sloan Kettering Cancer CenterStudy on Mosunetuzumab for People with Follicular Lymphoma
- 2022Merck Sharp & Dohme LLCStudy on Zilovertamab Vedotin as a Single Treatment and in Combination for Aggressive and Slow-Growing B-cell Blood Cancers
- 2021EnteromeStudy on a New Vaccine (EO2463) Alone and with Other Treatments for Indolent Non-Hodgkin Lymphoma
- 2021BeiGeneStudy on BGB-16673 for Patients with B-Cell Blood Cancers
- 2021H. Lee Moffitt Cancer Center and Research InstituteStudy on Improving Immunity with PCV13 Vaccine Before and After CAR-T Therapy
- 2021New York Medical CollegeStudy on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma
- 2020GenmabSafety and Effectiveness Study of Epcoritamab Combinations for B-cell Non-Hodgkin Lymphoma
- 2020Medical College of WisconsinStudy on CAR-20/19-T Cells for Patients with Hard-to-Treat B Cell Cancers
- 2020Epizyme, Inc.Study on Tazemetostat with Lenalidomide and Rituximab vs. Placebo for Adults with Relapsed/Refractory Follicular Lymphoma
- 2020Hoffmann-La RocheStudy on the Safety and Effectiveness of Mosunetuzumab and Lenalidomide for Follicular Lymphoma
- 2020University of Michigan Rogel Cancer CenterVorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
- 2019National Cancer Institute (NCI)Study on Copanlisib and Rituximab for Untreated Follicular Lymphoma
- 2019M.D. Anderson Cancer CenterStudy on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant
- 2018Xynomic Pharmaceuticals, Inc.Study on Abexinostat for Patients with Relapsed or Hard-to-Treat Follicular Lymphoma
- 2018Masonic Cancer Center, University of MinnesotaStudy on Myeloablative Stem Cell Transplant with Donor for Blood Disorders
- 2017ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers
- 2013Janssen Research & Development, LLCLong-term Study of Ibrutinib for Ongoing Access and Safety Monitoring
- 2021XEME Biopharma Inc.Study on Oncoquest-L Vaccine for Patients with Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Follicular Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
How access works: expanded access and Right to Try, explained in plain language.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.
